RS Crum Inc’s Pfizer PFE Stock Holding History

RS Crum Inc’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,679	Closed	-$216K	–	105
2026 Q1	$216K	Buy	+7,679	New	+$204K	0.04%	97
2025 Q1	–	Sell	-7,679	Closed	-$204K	–	90
2024 Q4	$204K	Sell	7,679 -194	-2%	-$5.26K	0.05%	87
2024 Q3	$228K	Buy	7,873 +69	+0.9%	+$2.01K	0.05%	87
2024 Q2	$218K	Hold	7,804	–	–	0.06%	88
2024 Q1	$217K	Hold	7,804	–	–	0.06%	78
2023 Q4	$225K	Hold	7,804	–	–	0.07%	76
2023 Q3	$259K	Buy	+7,804	New	+$276K	0.09%	69

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RS Crum Inc's PFE Position: Q2 2026 in Review

RS Crum Inc sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,679 shares — an estimated $216K sold.

RS Crum Inc first reported a position in PFE in Q3 2023 and held it in 7 quarters. The position peaked at $259K in Q3 2023. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

RS Crum Inc reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
RS Crum Inc sold 7,679 Pfizer shares in Q2 2026, an estimated $216K.
RS Crum Inc first reported a position in Pfizer in Q3 2023 and held it in 7 quarters.
RS Crum Inc's Pfizer position peaked at $259K in Q3 2023.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on RS Crum Inc's 13F filing for Q2 2026, filed 10 Aug 2026.